An Open-Label, Sequential and 2-Way Crossover Pharmacokinetic Study to Assess the Absolute Bioavailability of Oral PCI-32765 and the Effect of Grapefruit Juice on the Bioavailability of PCI-32765 in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 03 Nov 2016
Price : $35 *
At a glance
- Drugs Ibrutinib (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Multiple myeloma
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 01 Aug 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 18 Jun 2013 Planned End Date changed from 1 Jul 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.
- 18 Jun 2013 Planned initiation date changed from 1 May 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.